Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516607 | 0.89 | CXCR3 (0.50) | TRPV1CXCR3KDM4EGAA | |
| SCHEMBL2224011 | 0.86 | CXCR3 (0.45) | CXCR3KDM4EGAACACNA1HKCNH2 | |
| SCHEMBL2270318 | 0.86 | CXCR3 (0.45) | CXCR3KDM4EGAACACNA1HKCNH2 | |
| SCHEMBL12516605 | 0.86 | CXCR3 (0.46) | TRPV1CXCR3KDM4EGAA | |
| SCHEMBL2266970 | 0.83 | CXCR3 (0.64) | CXCR3GAACACNA1HKCNH2CACNA1I | |
| SCHEMBL2222302 | 0.81 | MEN1 (0.61) | CXCR3GAACACNA1HKCNH2CACNA1I | |
| SCHEMBL2223364 | 0.81 | CXCR3 (0.53) | CXCR3GAACACNA1HKCNH2CACNA1I | |
| SCHEMBL2221310 | 0.79 | CXCR3 (0.55) | CXCR3CACNA1HKCNH2CACNA1IACKR3 | |
| SCHEMBL2264590 | 0.79 | CXCR3 (0.53) | CXCR3CACNA1HKCNH2CACNA1I | |
| SCHEMBL2224894 | 0.76 | IDH2 (0.46) | CXCR3KDM4EGAAACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | claimed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | TRPV1 276/4885CXCR3 1/4885KDM4E 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.